Menopausal Hot Flashes Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Menopausal Hot Flashes Market is Segmented by Treatment Type (Hormonal Treatment (Estrogen, Progesterone, and Estrogen-Progesterone Combination) and Non-hormonal Treatment (Antidepressant and Other Non-hormonal Treatments)) and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Menopausal Hot Flashes Market Summary
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 3.4 %
Menopausal Hot Flashes Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The menopausal hot flashes market is projected to register a CAGR of 3.4% during the forecast period, 2022-2027.

Although the COVID-19 epidemic has continued to reverse the growth of various markets, the current impact of the outbreak varies. The high pressure for hospitals to provide services to COVID-19 patients was one of the main barriers to hospitals and clinics providing women's health services. According to the study titled "Inactive Lifestyles Lead to More Frequent, Severe Hot Flashes: Study" published in September 2021, in the age of COVID-19 sedentary behavior, working from home, traveling less has increased the prevalence of hot flashes and menopause in women, which has significantly impacted the market.

Increased incidence of menstrual fever, increased authorization of new therapies, and increased awareness of menopause health are important factors in driving the menopausal hot flashes market. Hot flashes are a feeling of sudden warmth, often intense on the chest, neck, and face. The heat causes redness of the skin (called flatulence) and excessive sweating. Hot flashes often occur as a result of menopause when menstruation is abnormal and eventually stops. Fever is the most common sign of menopause (including stages such as menopause, menopause, and post-menopause). The occurrence of hot flashes varies between women and can range from a few weeks to a few hours. Some of the symptoms of hot flashes are rapid heartbeat, red, swollen skin, sweating, especially in the upper extremities, the rapid sensation of warmth spreading over the face and face, and so on. Hot temperatures can vary in intensity and frequency. On average, fever symptoms persist for more than seven years or sometimes in some women, possibly for more than 10 years. Hot flashes are caused by changes in fertility hormones, which are more sensitive to small changes in body temperature. Factors such as smoking, obesity, and racism may increase the risk of hot flashes.

According to the study "Frequent hot flashes in women, 40 to 65 years of age with metabolic syndrome" published in December 2020, women over the age of 40 are more likely to have a fever, about 55.83%, and appear to be associated with metabolic syndrome.

In addition, according to a study "Hot Flashes" updated in December 2021 published in the National Center for Biotechnology Information (NCBI), hot flashes were among the most common types of menopausal vasomotor (VMS) symptoms, affecting up to 74% of perimenopausal women. About 65% of women complain of hot flashes for more than two years and 36% cry for more than five years. Therefore, the increasing incidence of menopausal vasomotor symptoms serves as a major factor contributing to the market growth of menopausal hot flashes.

Additionally, the increasing focus on research for the development of treatment of hot flashes is also propelling the growth of the market. For Instance, in December 2021, Acer Therapeutics Inc. received United States Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for its selective non-peptide neurokinin 3 receptors (NK3R) antagonist, ACER-801 (osanetant), for the potential treatment of induced Vasomotor Symptoms (iVMS).

Thus, due to the above-mentioned factors, the studied market is expected to witness significant growth during the study period. However, the side effects associated with hormone products and the availability of generic drugs are limiting factors to the growth of the market.

Scope of the Report

According to the scope of the report, menopausal hot flashes are the symptoms of menopause. They refer to feelings of warmth occurring during the menopause transition. In addition, hot flashes are the most common symptom of perimenopause, when ovaries gradually make less estrogen. The menopausal hot flashes market is segmented by treatment type (hormonal treatment (estrogen, progesterone, and estrogen-progesterone combination) and non-hormonal treatment (antidepressant and other non-hormonal treatments) and geography (North America, Europe, Asia-Pacific, the Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Treatment Type
Hormonal Treatment
Estrogen-Progesterone Combination
Non-hormonal Treatment
Other Non-hormonal Treatments
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle East and Africa
South Africa
Rest of Middle East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Estrogen Segment is Expected to Hold a Major Market Share in the Market

The COVID-19 epidemic has affected the supply chain of pharmaceutical products. The restrictions on the production and export of medicines have affected many imported products, such as the United States, Europe, and other countries. Some of the medicines are manufactured indoors by pharmaceutical companies, and some of the company's medicines are manufactured with foreign materials, such as contract production services, which also contributed to the supply of products.

Estrogen supplements help to increase female hormone levels and reduce the symptoms of menopause, including fever. Some of the United States Food and Drug Administration-approved estradiol-containing heat treatments are Alora, Estraderm, Estrogel, Evamist, Vivelle, Climara, Divigel, and Estrace.

According to the article "Hormone therapy: Is it right for you?" published in June 2020, systemic estrogen therapy remains the most effective treatment for the relief of troublesome menopausal hot flashes and night sweats. It can also ease vaginal symptoms of menopause, such as dryness, itching, burning, and discomfort with intercourse. Thus, the estrogen component plays a major role in the market for menopausal hot flashes and is expected to show a similar trend in the forecast period.

Additionally, the study "Treatment of menopausal symptoms with hormone therapy" published in June 2020 suggested that estrogen is the most effective treatment available for relief of hot flashes and other menopausal symptoms as well such as vulvovaginal atrophy, including vaginal dryness and dyspareunia.

Some of the benefits associated with estrogen medications include improving the health of the vagina, reducing the symptoms of menopause, and possibly promoting bone and heart health.

Novartis AG provides "Vivelle-DOT (estradiol transdermal system)" which is used to treat moderate and severe vasomotor symptoms due to menopause and to treat moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. In addition, the company Novo Nordisk Corporation offers a "Vagifem" 10 mcg tablet for vagin that treats changes in and around the vagina that occur after menopause and treats a combination of vaginal symptoms.

Therefore, the increased incidence of menopausal fever and technological advances in the development of new drugs by emerging athletes in the market are the main components of the estrogen component.

Menopausal Hot Flashes Market : Total Number of Clinical Trails for Menopausal Hot Flashes, By Phase, Global, As of 21 March 2022

North America is Expected to Hold a Significant Share in the Market and Continue the Trend over the Forecast Period

North America is expected to hold a major market share in the menopausal hot flashes market due to the increased incidence of menopause, increased awareness of menopause, and the presence of a large percentage of older women in the region. According to the February 2022 update of "Menopause (Nursing)" by Kimberly Peacock et al., stated that in the United States, about 1.3 million women stop menstruating each year, starting between the ages of 51 and 52 years. According to the same source, about 5% of women experience premature menopause between the ages of 40 and 45.

In addition, good government-initiated policies, such as Healthy People 2020, developed by the Department of Health and Human Services, which has a 10-year plan to improve the health of all Americans, are likely to further market growth.

Furthermore, the launch of products and approvals from the regulatory authority also propel the growth of the market. For Instance, in May 2021, TherapeuticsMD, Inc. submitted a supplemental New Drug Application (“sNDA”) for BIJUVA (estradiol and progesterone) capsules, 0.5 mg/100 mg, to the United States Food and Drug Administration (“FDA”). BIJUVA is the only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule. It is taken once daily for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.

Thus, owing to the abovementioned factors, the market is expected to grow in the North American region over the forecast period.

Menopausal Hot Flashes Market : Growth Rate by Region

Competitive Landscape

The menopausal hot flashes market is fragmented and competitive and consists of several major players. A large portion of the market share is taken up by small and mid-sized companies that produce generic treatment options. Some of the companies currently dominating the market are AbbVie Inc. (Allergan PLC), Bayer AG, Novartis AG, Pfizer Inc., Novo Nordisk Corporation, Hisamitsu Pharmaceutical Co. Inc., Merck & Co. Inc., and Teva Pharmaceutical Industries Ltd.

Recent Developments

  • In June 2022, Astellas Pharma Inc. submitted aNew Drug Application (NDA) for fezolinetant has been submitted to the U.S. Food and Drug Administration (FDA). Fezolinetant is an investigational oral, nonhormonal compound seeking approval for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
  • In April 2022, Fervent Pharmaceuticals initiated a virtual at-home Phase II clinical trial of its new product to treat the symptoms of moderate to severe hot flashes, night sweats, and night-time awakenings due to hot flashes in women. The study is named as M2S Hot Flash Study, the trial will analyze the peri- and post-menopausal therapy to treat hot flashes and night sweats.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Incidence of Menopausal Vasomotor Symptoms

      2. 4.2.2 Technological Advancements in the Development of New Drugs for Treatment

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effects Associated with Hormonal Products

      2. 4.3.2 Availability of Generic Medicines

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD Millions)

    1. 5.1 By Treatment Type

      1. 5.1.1 Hormonal Treatment

        1. Estrogen

        2. Progesterone

        3. Estrogen-Progesterone Combination

      2. 5.1.2 Non-hormonal Treatment

        1. Antidepressant

        2. Other Non-hormonal Treatments

    2. 5.2 Geography

      1. 5.2.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.2.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.2.4 Middle East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East and Africa

      5. 5.2.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 AbbVie Inc. (Allergan PLC)

      2. 6.1.2 Bayer AG

      3. 6.1.3 Novartis AG

      4. 6.1.4 Pfizer Inc.

      5. 6.1.5 Novo Nordisk Corporation

      6. 6.1.6 Hisamitsu Pharmaceutical Co. Inc.

      7. 6.1.7 Merck & Co. Inc.

      8. 6.1.8 Teva Pharmaceutical Industries Ltd

      9. 6.1.9 Agile Therapeutics

      10. 6.1.10 Amgen Inc.

      11. 6.1.11 AstraZeneca PLC

      12. 6.1.12 Bristol-Myers Squibb Company

      13. 6.1.13 Ferring BV

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Menopausal Hot Flashes Market market is studied from 2019 - 2027.

The Global Menopausal Hot Flashes Market is growing at a CAGR of 3.4% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Bayer AG, Novartis AG, Pfizer, Inc, Novo Nordisk Corporation, AbbVie Inc.(Allergan Plc) are the major companies operating in Global Menopausal Hot Flashes Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!